Top 5 Drug Type | Count |
---|---|
Small molecule drug | 11 |
Vaccine | 1 |
Target |
Mechanism ETA antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Mar 2024 |
Target |
Mechanism S1PR1 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date18 Mar 2021 |
Target |
Mechanism PGI2 receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date21 Dec 2015 |
Start Date30 Sep 2024 |
Sponsor / Collaborator Duke University [+1] |
Start Date11 Aug 2024 |
Sponsor / Collaborator |
Start Date14 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Selexipag ( PGI2 receptor ) | Pulmonary Arterial Hypertension More | Approved |
Miglustat ( UGCG ) | Niemann-Pick Diseases More | Approved |
Macitentan/Tadalafil ( ETA x ETB x PDE5A ) | Pulmonary Arterial Hypertension More | Approved |
Iloprost ( PGI2 receptor ) | Chilblains More | Approved |
Bosentan ( ETA x ETB ) | Pulmonary Arterial Hypertension More | Approved |